View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Általános Orvostudományi Kar Belgyógyászati Intézet, III. Belgyógyászati Klinika Debrecen Móricz Zs. krt. 22. 4032
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Napjainkban a legtöbb Hodgkin-lymphomás beteg meggyógyítható a korszerű kezelési módszerekkel, sajnos a betegek néhány százaléka refrakter, és közel harmaduk relabál az elsődleges kezelést követően. Célkitűzés és módszer: a DEOEC III. sz. Belgyógyászati Klinikán 1996 és 2006 között kezelt Hodgkin-lymphomás beteg között vizsgáltuk retrospektív módszerrel a refrakter esetek és a relapszusok előfordulását. Eredmények: 76 nő és 71 férfi esetében diagnosztizáltunk Hodgkin-lymphomát ezen idő alatt. A betegek 95,9%-a került remisszióba az elsődleges kezelésre. 6 nőbeteg volt primeren refrakter, 4 betegnél autológ hemopoetikus őssejttranszplantáció is történt, de a többszörös kezelések ellenére is mindannyian exitáltak. 31 betegnél alakult ki relapszus (1 éven belül 16 esetben). 14 betegnél történt autológ hemopoetikus őssejttranszplantáció, 11 beteg csak kemoterápiában, 3 csak irradiációban és 3 beteg kombinált kezelésben részesült. A relabált betegek közül öten alapbetegségük progressziója, egy beteg szekunder myelodysplasia miatt exitált. Következtetések: a relabált betegek prognózisa a további kezelések mellett jó lehet, de a refrakter betegek hosszú távú esélyei rendkívül rosszak még autológ-, és akár allogén hemopoetikus őssejttranszplantáció mellett is, így rendkívül fontos az újabb kezelési módszerek keresése.

  • Lukes, R. J., Craver, L. F., Hall, T. C.: Report of the nomenclatura committee. Cancer Res., 1966, 26 , 1311.

    Hall T. C. , 'Report of the nomenclatura committee ' (1966 ) 26 Cancer Res. : 1311 -.

  • Harris, N. L., Jaffe, E. S., Diebold, J. és mtsai: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology, 2000, 36 , 69–89.

    Diebold J. , 'The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 ' (2000 ) 36 Histopathology : 69 -89.

    • Search Google Scholar
  • Carbone P. P., Kaplan, H. S., Musshoff K: Report of the committee on Hodgkin’s disease staging classification. Cancer. Res., 1971, 31 , 1860–1861.

    Musshoff K. , 'Report of the committee on Hodgkin’s disease staging classification ' (1971 ) 31 Cancer. Res. : 1860 -1861.

    • Search Google Scholar
  • Lister, T. A., Crowther, D., Sutcliffe, S. B. és mtsai: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol., 1989, 7 , 1630–1636.

    Sutcliffe S. B. , 'Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting ' (1989 ) 7 J. Clin. Oncol. : 1630 -1636.

    • Search Google Scholar
  • Tubiana, M., Henry-Amar, M., Carde, P. és mtsai: Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood, 1989, 73 , 47–56.

    Carde P. , 'Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987 ' (1989 ) 73 Blood : 47 -56.

    • Search Google Scholar
  • Hasenclever, D., Diehl, V.: A prognostic score for advanced Hodgkin’s disease. N. Eng. J. Med., 1998, 339 , 1506–1514.

    Diehl V. , 'A prognostic score for advanced Hodgkin’s disease ' (1998 ) 339 N. Eng. J. Med. : 1506 -1514.

    • Search Google Scholar
  • Josting, A., Rueffer, U., Franklin, J. és mtsai: Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood, 2000, 96 , 1280–1286.

    Franklin J. , 'Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group ' (2000 ) 96 Blood : 1280 -1286.

    • Search Google Scholar
  • Diehl, V., Franklin, J., Pfreundschuh, M. és mtsai: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N. Eng. J. Med., 2003, 348 , 2386–2395.

    Pfreundschuh M. , 'Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease ' (2003 ) 348 N. Eng. J. Med. : 2386 -2395.

    • Search Google Scholar
  • Diehl, V.: New aspects in advanced stages 2009, 3rd International Symposium on Hodgkin lymphoma Prague, 2009. September 17–18 Prague

  • Schmitz, N., Pfistner, B., Sextro, M. és mtsai: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet, 2002, 359 , 2065–2071.

    Sextro M. , 'Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial ' (2002 ) 359 Lancet : 2065 -2071.

    • Search Google Scholar
  • Schmitz, N., Haverkamp, H., Josting, A. és mtsai: Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT).; J. Clin. Oncol., 2005, ASCO Annual Meeting Proceedings 23, 6508.

  • Brice, P.: Managing relapsed and refractory Hodgkin lymphoma. Br. J. Haematol., 2008, 141 , 3–13.

    Brice P. , 'Managing relapsed and refractory Hodgkin lymphoma ' (2008 ) 141 Br. J. Haematol. : 3 -13.

    • Search Google Scholar
  • Lohri, A., Barnett, M., Fairey, R. N. és mtsai: Outcome of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1980. Blood, 1991, 77 , 2292–2298.

    Fairey R. N. , 'Outcome of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1980 ' (1991 ) 77 Blood : 2292 -2298.

    • Search Google Scholar
  • Brice, P., Bastion, Y., Diviné, M. és mtsai: Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer, 1996, 78 , 1293–1299.

    Diviné M. , 'Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients ' (1996 ) 78 Cancer : 1293 -1299.

    • Search Google Scholar
  • Moskowitz, C. H., Nimer, S. D., Zelenetz, A. D. és mtsai: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 2001, 97 , 616–623.

    Zelenetz A. D. , 'A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model ' (2001 ) 97 Blood : 616 -623.

    • Search Google Scholar
  • Josting, A., Franklin, J., Sieber, M. és mtsai: Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. J. Clin. Oncol., 2002, 20 , 220–231.

    Sieber M. , 'Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group ' (2002 ) 20 J. Clin. Oncol. : 220 -231.

    • Search Google Scholar
  • Canioni, D., Deau-Fischer, B., Taupin, P. és mtsai: Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases. PLoS One, 2009, 4 , 6341.

    Taupin P. , 'Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases ' (2009 ) 4 PLoS One : 6341 -.

    • Search Google Scholar
  • Jabbour, E., Hosing, C., Pro, B. és mtsai: Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin lymphoma (HL), 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol., 2005, 23 , 6509.

    Pro B. , 'Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin lymphoma (HL), 2005 ASCO Annual Meeting Proceedings ' (2005 ) 23 J. Clin. Oncol. : 6509 -.

    • Search Google Scholar
  • Cashen, A. F., Bartlett, N. L.: Therapy of relapsed Hodgkin lymphoma. Blood Rev., 2007, 21 , 233–243.

    Bartlett N. L. , 'Therapy of relapsed Hodgkin lymphoma ' (2007 ) 21 Blood Rev. : 233 -243.

  • Santoro, A., Magagnoli, M., Spina, M. és mtsai: Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica, 2007, 92 , 35–41.

    Spina M. , 'Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma ' (2007 ) 92 Haematologica : 35 -41.

    • Search Google Scholar
  • Josting, A., Nogova, L., Franklin, J. és mtsai: Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J. Clin. Oncol., 2005, 23 , 1522–1529.

    Franklin J. , 'Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group ' (2005 ) 23 J. Clin. Oncol. : 1522 -1529.

    • Search Google Scholar
  • Sureda, A., Arranz, R., Iriondo, A.: Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J. Clin. Oncol., 2001, 19 , 1395–1404.

    Iriondo A. , 'Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group ' (2001 ) 19 J. Clin. Oncol. : 1395 -1404.

    • Search Google Scholar
  • Younes, A., Romaguera, J., Hagemeister, F. és mtsai: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer, 2003, 98 , 310–314.

    Hagemeister F. , 'A pilot study of rituximab in patients with recurrent, classic Hodgkin disease ' (2003 ) 98 Cancer : 310 -314.

    • Search Google Scholar
  • Goy, A., Fayad, L., Romaguera, J.: Preliminary report of a phase II study of vincristine sulfate liposomes injection (VSLI) in patients with relapsed or refractory Hodgkin’s disease. Eur. J. Haematol., 2004, 73 , 54.

    Romaguera J. , 'Preliminary report of a phase II study of vincristine sulfate liposomes injection (VSLI) in patients with relapsed or refractory Hodgkin’s disease ' (2004 ) 73 Eur. J. Haematol. : 54 -.

    • Search Google Scholar
  • Zheng, B., Georgakis, G. V., Li, Y. és mtsai: Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors. Clin. Cancer Res., 2004, 10 , 3207–3215.

    Li Y. , 'Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors ' (2004 ) 10 Clin. Cancer Res. : 3207 -3215.

    • Search Google Scholar
  • Younes, A., Pro, B., Fayad, L.: Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 2006, 1007 , 1731–1732.

    Fayad L. , 'Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma ' (2006 ) 1007 Blood : 1731 -1732.

    • Search Google Scholar
  • Blum, K. A., Johnson, J. L., Niedzwiecki, D.: A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206. J. Clin. Oncol., 2006, 24 , 7576.

    Niedzwiecki D. , 'A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206 ' (2006 ) 24 J. Clin. Oncol. : 7576 -.

    • Search Google Scholar
  • Quddus, F., Armitage, J. O.: Salvage therapy for Hodgkin’s lymphoma. Cancer J., 2009, 15 , 161–163.

    Armitage J. O. , 'Salvage therapy for Hodgkin’s lymphoma ' (2009 ) 15 Cancer J. : 161 -163.

  • Iványi, J., Kiss, A., Telek, B. és mtsai: Hodgkin-kóros betegeink kezelésével szerzett tapasztalataink (1975–1986). Orv. Hetil., 1988, 129 , 339–346.

    Telek B. , 'Hodgkin-kóros betegeink kezelésével szerzett tapasztalataink (1975–1986) ' (1988 ) 129 Orv. Hetil. : 339 -346.

    • Search Google Scholar
  • Fleischmann, T.: A malignus limfomák kutatása és gyógyítása. Magyar Tudomány, 1986, 31 , 568–575.

    Fleischmann T. , 'A malignus limfomák kutatása és gyógyítása ' (1986 ) 31 Magyar Tudomány : 568 -575.

    • Search Google Scholar
  • Simon, Z., Keresztes, K., Miltényi, Z. és mtsai: Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalataink az utóbbi évtizedben. Orv. Hetil., 2007, 148 , 675–682.

    Miltényi Z. , 'Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalataink az utóbbi évtizedben ' (2007 ) 148 Orv. Hetil. : 675 -682.

    • Search Google Scholar